Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

View Full Paper
Ask AI
Bookmark
Share

Authors

JTJose TinajeroHMHuiyan MaSPSunmin Park

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows RAS pathway mutations affect survival and relapse incidence in acute myeloid leukemia patients post-allogeneic transplant, suggesting improved outcomes may require clearer

Key Points

  • Persistence of RAS pathway mutations pre-transplant significantly decreases overall survival and leukemia free survival.
  • Survival rates at 2 and 5 years were 56.7% and 47.7% for overall survival, with 53.5% and 48.4% for leukemia free survival.
  • Analysis of patients undergoing allogeneic transplant used next generation sequencing to examine RAS mutations pre- and post-transplant.
  • Finding indicates that addressing RAS mutations before transplant could enhance treatment outcomes in acute myeloid leukemia.

Cite This Study

Tinajero et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5e9https://doi.org/10.1182/blood-2025-4305
View Full Paper
Ask AI
Bookmark
Share